DARMSTADT, Germany -Monday 22 November 2021 [ AETOS Wire ]
5 potential first-in-class assets aimed at delivering significant long-term growth
14 clinical development programs underway across portfolio
11 new studies to start in 2022 across early- and late-stage pipeline
(BUSINESS WIRE)-- Merck, a leading science and technology company, today provided an overview of its innovative pipeline with a focus on five mid- to late-stage assets with first-in-class and/or best-in-class potential at its R&D Update Call.
“At Merck we are working to translate our extensive expertise and deep knowledge in key tumors and neurological and immunological diseases with a goal to change treatment paradigms and improve patient outcomes,” said Danny Bar-Zohar, Global Head of Development for the Healthcare business of Merck. “With evobrutinib, xevinapant, and berzosertib, we have the opportunity to be not only first-in-class, but potential game-change
Read more »